Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 49.79% is in line with its 5-year average of 51.77%, near the low end of its 5-year range (46.21%–59.73%).
0.54% above its 12-month average of 49.52%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 51.90%.
GROSS MARGIN
49.79%
GROSS MARGIN AVG TTM
49.52%
GROSS MARGIN AVG 3Y
50.52%
GROSS MARGIN AVG 5Y
51.77%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.54%
CURRENT VS 3Y AVG
-1.44%
CURRENT VS 5Y AVG
-3.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 809 covered companies
CURRENT VS SECTOR MEDIAN
+23.12%
vs the sector median at left
908 Devices Inc.
Market Cap
$511.61M
Gross Margin
49.79%
TTM Avg
49.52%
3Y Avg
50.52%
5Y Avg
51.77%
Market Cap
$507.38M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
-2215.86%
5Y Avg
-1460.58%
Market Cap
$517.30M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
31.77%
Market Cap
$503.30M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
83.33%
Market Cap
$521.32M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$520.90M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$498.49M
Gross Margin
74.23%
TTM Avg
74.56%
3Y Avg
72.89%
5Y Avg
72.29%
Market Cap
$494.94M
Gross Margin
0.00%
TTM Avg
-3746.14%
3Y Avg
-1873.07%
5Y Avg
-1248.71%
Market Cap
$531.92M
Gross Margin
82.92%
TTM Avg
86.33%
3Y Avg
62.04%
5Y Avg
41.36%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 908 Devices Inc. (MASS) | $511.61M | 49.79% | 49.52% | 50.52% | 51.77% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $507.38M | 0.00% | 50.00% | -2215.86% | -1460.58% |
| Altimmune, Inc. (ALT)vs › | $517.30M | 100.00% | 100.00% | 100.00% | 31.77% |
| Crescent Biopharma, Inc. (CBIO)vs › | $503.30M | 100.00% | 50.00% | 75.00% | 83.33% |
| Monopar Therapeutics Inc. (MNPR)vs › | $521.32M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $520.90M | 0.00% | 0.00% | 0.00% | 0.00% |
| Tactile Systems Technology, Inc. (TCMD)vs › | $498.49M | 74.23% | 74.56% | 72.89% | 72.29% |
| Oculis Holding AG (OCS)vs › | $494.94M | 0.00% | -3746.14% | -1873.07% | -1248.71% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $531.92M | 82.92% | 86.33% | 62.04% | 41.36% |
| ProKidney Corp. (PROK)vs › | $532.96M | 100.00% | 100.00% | 50.00% | 33.33% |
Gross Margin
49.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 51.90% |
| 2026-03-31 | 47.66% |
| 2025-12-31 | 49.90% |
| 2025-09-30 | 49.26% |
| 2025-06-30 | 48.89% |
| 2025-03-31 | 47.05% |
| 2024-12-31 | 48.74% |
| 2024-09-30 | 53.57% |
| 2024-06-30 | 53.76% |
| 2024-03-31 | 52.37% |
| 2023-12-31 | 50.69% |
| 2023-09-30 | 55.04% |
| 2023-06-30 | 47.91% |
| 2023-03-31 | 46.21% |
| 2022-12-31 | 50.86% |
| 2022-09-30 | 59.11% |
| 2022-06-30 | 59.73% |
| 2022-03-31 | 49.71% |
| 2021-12-31 | 57.66% |
| 2021-09-30 | 54.30% |
| 2021-06-30 | 52.91% |
| 2021-03-31 | 52.46% |
| 2020-12-31 | 45.11% |
| 2020-09-30 | 63.43% |
| 2020-06-30 | 57.60% |
| 2020-03-31 | 52.44% |
| 2019-12-31 | 51.92% |
| 2019-09-30 | 24.43% |
| 2019-06-30 | 47.25% |
| 2019-03-31 | 48.03% |
